Active Not RecruitingNCT04105231
Cannabidiol or risperidone for psychosis in people who have used cannabis
About this title
Read the official source — NCT04105231Medication studyAges 18–45DenmarkSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 45 years.
- Listed locations
- Glostrup MunicipalitySee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 1, 2021
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 64
- Sponsor
- Lone Baandrup
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT04105231
- Official title
Show the full official title
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glostrup Municipality
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Lone Baandrup.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol and Risperidone.
Who can participate?
Listed age limits: 18 years to 45 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
